Morgan Stanley T Scan Therapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 223,894 shares of TCRX stock, worth $1.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

223,894

Previous 234,703 4.61%

Holding current value

$1.91 Million

Previous $1.37 Million 29.9%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.89 - $8.3 $52,856 - $89,714	-10,809 Reduced 4.61%	223,894 $1.78 Million
Q4 2023 Feb 13, 2024	SELL	$2.66 - $6.76 $65,819 - $167,269	-24,744 Reduced 9.54%	234,703 $1.37 Million
Q3 2023 Nov 15, 2023	BUY	$2.04 - $2.94 $307,982 - $443,857	150,972 Added 139.18%	259,447 $664,000
Q2 2023 Aug 14, 2023	SELL	$1.64 - $4.85 $37,464 - $110,793	-22,844 Reduced 17.4%	108,475 $271,000
Q1 2023 May 15, 2023	BUY	$1.66 - $3.32 $147,979 - $295,958	89,144 Added 211.37%	131,319 $275,000

Q4 2022 Feb 14, 2023	SELL	$1.49 - $2.86 $33,368 - $64,049	-22,395 Reduced 34.68%	42,175 $65,000
Q3 2022 Nov 14, 2022	BUY	$2.62 - $4.39 $19,600 - $32,841	7,481 Added 13.1%	64,570 $197,000
Q2 2022 Oct 27, 2022	BUY	$1.65 - $3.58 $29,721 - $64,486	18,013 Added 46.1%	57,089 $180,000
Q2 2022 Aug 15, 2022	BUY	$1.65 - $3.58 $29,721 - $64,486	18,013 Added 46.1%	57,089 $180,000
Q1 2022 Oct 27, 2022	SELL	$2.8 - $5.4 $50,436 - $97,270	-18,013 Reduced 31.55%	39,076 $110,000
Q1 2022 May 13, 2022	BUY	$2.8 - $5.4 $32,681 - $63,028	11,672 Added 42.59%	39,076 $110,000
Q4 2021 Feb 14, 2022	SELL	$4.5 - $9.05 $3,744 - $7,529	-832 Reduced 2.95%	27,404 $123,000
Q3 2021 Nov 15, 2021	BUY	$6.17 - $13.48 $174,216 - $380,621	28,236 New	28,236 $235,000

Others Institutions Holding TCRX

# of Institutions

Shares Held

29.3M

Call Options Held

Put Options Held

View Full List

About TScan Therapeutics, Inc.

Ticker TCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,929,800
Market Cap $162M
Description
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...

More about TCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account